title: Early surfactant administration protects against lung dysfunction in a mouse model of ARDS.
abstract: Sepsis can predispose the lung to insults such as mechanical ventilation (MV). It was hypothesized that treating the lung with exogenous surfactant early in the development of sepsis will reduce the lung dysfunction associated with MV 18 h later. Mice underwent sham or cecal ligation and perforation (CLP) surgery. Immediately after surgery, mice were either untreated or given 100 mg/kg of bovine lipid extract surfactant intratracheally. Eighteen hours later, the lungs were removed and analyzed either immediately or following ventilation ex vivo for 2 h by an "injurious" mode of ventilation (20 ml/kg, 0 cm positive end-expiratory pressure). In nonventilated lungs, exogenous surfactant had no impact on compliance or IL-6 concentrations in the lungs. In the ventilated groups, the administered surfactant had a significant protective effect on the lung dysfunction induced by MV, but only in the CLP lungs. We conclude that administration of exogenous surfactant at the time of a systemic insult can protect the lung from the damaging effects of MV 18 h later.
authors.affiliation: Department of Physiology, Lawson Health Research Institute, University of Western Ontario, London, Ontario N6A 4V2, Canada.
authors.forename: Vijay P A
authors.initials: VP
authors.lastname: Rasaiah
authors.forename: Jaret L
authors.initials: JL
authors.lastname: Malloy
authors.forename: James F
authors.initials: JF
authors.lastname: Lewis
authors.forename: Ruud A W
authors.initials: RA
authors.lastname: Veldhuizen
mesh_terms: D000208:Acute Disease; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D004195:Disease Models, Animal; D015850:Interleukin-6 / Q000032:analysis; D008170:Lung Compliance / Q000187:drug effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011663:Pulmonary Surfactants / Q000493:pharmacokinetics*; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000209:etiology; D018805:Sepsis / Q000150:complications; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D015850:Interleukin-6; D011663:Pulmonary Surfactants; D014409:Tumor Necrosis Factor-alpha